Adoptive T-Cell Therapy for Cancer: New Developments as Scientists and Investigators Share Insight on Improving Efficiency and Efficacy

Share Article

Laboratory heads and directors, clinical investigators and scientists will share their latest insight on cancer models and the efficiency and efficacy on liquid and solid tumours, T-cell engineering and investigation in human and clinical studies amongst other topics at Kisaco Research's Adoptive T-Cell Therapy Congress in London this March.

Although adoptive T-cell therapy, including the C19 CAR T, continues to show its potential benefits in immunotherapy and effectiveness in remissions, critical questions remain: How is safety against toxicity being addressed, what is the best practice response for mutations, how can translation in the clinic be efficiently managed?

Most importantly, what new developments are being made and what does that mean for the cancer treatment industry?

In order to address these questions, laboratory heads and directors, clinical investigators and scientists will share their latest insight on cancer models and the efficiency and efficacy on liquid and solid tumours, T-cell engineering and investigation in human and clinical studies amongst other topics at the Adoptive T-Cell Therapy Congress in London this March. (http://www.tcellcongress.com)

Renier Brentjens, the Director at the Cellular Therapeutic Centre, Memorial Sloan Kettering Cancer Center, will deliver novel data on a next generation of CAR T cells, termed ‘armored CARs’ and discuss promising pre-clinical studies utilising them and Inge Marie Svane from the University of Copenhagen will explore the indication and combinations of TIL based adoptive cell therapy.

“What has to happen now, and is already happening, is that our group and others are targeting antigens on solid tumours. There is now a strong push to move this technology forward to see if we can get some promising clinical results in solid tumours, like breast cancer, prostate cancer, ovarian cancer and many others,” says Renier Brentjens.

The meeting revolves around therapies as they pertain to cancer research; however, as the benefits of T-cell therapy prove applicable to other diseases such as Severe Combined Immunodeficiency, the discussions onsite are designed to focus on academic collaboration and networking. Other speakers include Professor Hans Stauss, Royal Free Hospital; Emma Morris, University College London; and Wei Dong Han, The General Hospital of PLA in China.

With its life-changing potential, the immunotherapy industry is vast with both challenges and opportunities. At the start of 2016, Tmunity Therapeutics, raised $10 million in an equity financing in order to develop novel productsand several studies have been push forward using adoptive T-cells against gynaecological malignancies.

The Adoptive T-Cell Therapy Congress will take place from 15-16 March 2016 at the Millennium Hotel Knightsbridge in London, UK. Complete event information is available online at http://www.tcellcongress.com. Reduced rates are available for academics, students and post-doctoral researchers; conference pass fees will apply.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kim Vigilia
@NextinPharma
since: 06/2015
Follow >
Kisaco Research

Visit website